International Flavors & Fragrances Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
Fourth Quarter 2023 Consolidated.
Strides Board approves demerger of its Biotech business under Stelis Biopharma
Bengaluru, Feb 4 (UNI) Strides Pharma Science Limited (Strides), Bengaluru headquartered global Pharmaceutical Company on Thursday announced that its Board of Directors have approved in principle the demerger of its biotech business under Stelis Biopharma (Stelis).
The demerger is expected to unlock significant value for Strides shareholders.
A Committee will be formed to explore various options of value discovery including listing of the business on a standalone basis and recommend to the Audit Committee, Committee of Independent Directors and Board including the Scheme, swap ratio and way forward, according to a release here on Thursday.
Aditya Puri to Chair the Board of Stelis Biopharma, the proposed demerged Biotech Business of Strides
Posted On: 2021-02-04 01:37:49 (Time Zone: Arizona, USA)
Strides Pharma Science Limited (Strides) today announced that the Board of Directors of the Company have approved in principle the demerger of its biotech business under Stelis Biopharma (Stelis). The demerger is expected to unlock significant value for Strides shareholders.
The Board will form a Committee of Directors to explore various options of value discovery including listing of the business on a standalone basis. The Committee will recommend the proposals to the Audit Committee, Committee of Independent Directors and Board including the Scheme, swap ratio and way forward.